Logo image of INAB

IN8BIO INC (INAB) Stock Fundamental Analysis

NASDAQ:INAB - Nasdaq - US45674E1091 - Common Stock - Currency: USD

0.2715  -0.01 (-5.07%)

After market: 0.2703 0 (-0.44%)

Fundamental Rating

1

INAB gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. INAB may be in some trouble as it scores bad on both profitability and health. INAB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year INAB has reported negative net income.
INAB had a negative operating cash flow in the past year.
In the past 5 years INAB always reported negative net income.
INAB had a negative operating cash flow in each of the past 5 years.
INAB Yearly Net Income VS EBIT VS OCF VS FCFINAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -199.64%, INAB is doing worse than 90.41% of the companies in the same industry.
With a Return On Equity value of -371.16%, INAB is not doing good in the industry: 77.44% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -199.64%
ROE -371.16%
ROIC N/A
ROA(3y)-70.01%
ROA(5y)-156.5%
ROE(3y)-94.72%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INAB Yearly ROA, ROE, ROICINAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 500 -500 1K 1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for INAB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INAB Yearly Profit, Operating, Gross MarginsINAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for INAB has been increased compared to 1 year ago.
INAB has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, INAB has an improved debt to assets ratio.
INAB Yearly Shares OutstandingINAB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
INAB Yearly Total Debt VS Total AssetsINAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -14.77, we must say that INAB is in the distress zone and has some risk of bankruptcy.
INAB has a worse Altman-Z score (-14.77) than 81.88% of its industry peers.
INAB has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
INAB has a Debt to Equity ratio of 0.05. This is in the lower half of the industry: INAB underperforms 62.70% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -14.77
ROIC/WACCN/A
WACCN/A
INAB Yearly LT Debt VS Equity VS FCFINAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 20M -20M

2.3 Liquidity

INAB has a Current Ratio of 1.84. This is a normal value and indicates that INAB is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of INAB (1.84) is worse than 78.69% of its industry peers.
A Quick Ratio of 1.84 indicates that INAB should not have too much problems paying its short term obligations.
INAB has a worse Quick ratio (1.84) than 76.91% of its industry peers.
Industry RankSector Rank
Current Ratio 1.84
Quick Ratio 1.84
INAB Yearly Current Assets VS Current LiabilitesINAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 35.90% over the past year.
EPS 1Y (TTM)35.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.78%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, INAB will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.02% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y43.45%
EPS Next 2Y30.5%
EPS Next 3Y18.23%
EPS Next 5Y15.02%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
INAB Yearly Revenue VS EstimatesINAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
INAB Yearly EPS VS EstimatesINAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.5 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INAB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INAB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INAB Price Earnings VS Forward Price EarningsINAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INAB Per share dataINAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as INAB's earnings are expected to grow with 18.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.5%
EPS Next 3Y18.23%

More info and screens

0

5. Dividend

5.1 Amount

INAB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IN8BIO INC

NASDAQ:INAB (2/21/2025, 8:00:01 PM)

After market: 0.2703 0 (-0.44%)

0.2715

-0.01 (-5.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-13 2025-03-13/amc
Inst Owners31.45%
Inst Owner Change180.22%
Ins Owners8.84%
Ins Owner Change15.27%
Market Cap19.68M
Analysts80
Price Target4.85 (1686.37%)
Short Float %0.76%
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.39%
Min EPS beat(2)-10.88%
Max EPS beat(2)8.09%
EPS beat(4)1
Avg EPS beat(4)-11.88%
Min EPS beat(4)-34.27%
Max EPS beat(4)8.09%
EPS beat(8)4
Avg EPS beat(8)-5.51%
EPS beat(12)6
Avg EPS beat(12)-5.16%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-35.59%
EPS NQ rev (1m)2.18%
EPS NQ rev (3m)46.43%
EPS NY rev (1m)0%
EPS NY rev (3m)5.88%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.29
P/tB 2.29
EV/EBITDA N/A
EPS(TTM)-0.75
EYN/A
EPS(NY)-0.3
Fwd EYN/A
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0
BVpS0.12
TBVpS0.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -199.64%
ROE -371.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-70.01%
ROA(5y)-156.5%
ROE(3y)-94.72%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.42%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.84
Quick Ratio 1.84
Altman-Z -14.77
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)230.05%
Cap/Depr(5y)204.03%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.78%
EPS Next Y43.45%
EPS Next 2Y30.5%
EPS Next 3Y18.23%
EPS Next 5Y15.02%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.01%
EBIT Next 3Y-4.94%
EBIT Next 5Y-7.96%
FCF growth 1Y-20.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-36.08%
OCF growth 3YN/A
OCF growth 5YN/A